Abstract
Hepatocerebral disorders are serious neuropsychiatric conditions that result from liver failure. These disorders are characterized neuropathologically by varying degrees of neuronal cell death in basal ganglia, cerebellum, and spinal cord, and include clinical entities such as Wilson’s Disease, post-shunt myelopathy, hepatic encephalopathy, and acquired non-Wilsonian hepatocerebral degeneration. Morphologic changes to astrocytes (Alzheimer type II astrocytosis) are a major feature of hepatocerebral disorders. Neurological symptoms include Parkinsonism, cognitive dysfunction, and ataxia. Pathophysiologic mechanisms responsible for cerebral dysfunction and neuronal cell death in hepatocerebral disorders include ammonia toxicity and neurotoxic effects of metals such as copper, manganese, and iron. Molecular mechanisms of neurotoxicity include oxidative/nitrosative stress, glutamate (NMDA)-receptor-mediated excitotoxicity, and neuroinflammatory mechanisms. However, neuronal cell death in hepatocerebral disorders is limited by adaptive mechanisms that may include NMDA-receptor down-regulation, the synthesis of neuroprotective steroids and hypothermia. Management and treatment of hepatocerebral disorders include chelation therapy (Wilson’s Disease), the use of ammonia-lowering agents (lactulose, antibiotics, ornithine aspartate) and liver transplantation.
Similar content being viewed by others
References
Ahboucha S, Pomier-Layrargues G, Mamer O, Butterworth RF (2005) Increased brain concentrations of a neuroinhibitory steroid in human hepatic encephalopathy. Ann Neurol 58(1):169–170
Aschner M, Gannon M, Kimelberg HK (1992) Manganese uptake and efflux in cultured rat astrocytes. J Neurochem 58(2):730–735
Bechar M, Freud M, Kott E, Kott I, Kravvic H, Stern J, Sandbank U, Bornstein B (1970) Hepatic cirrhosis with post-shunt myelopathy. J Neurol Sci 11(2):101–107
Butterworth RF (1993) Portal-systemic encephalopathy: a disorder of neuron-astrocytic metabolic trafficking. Dev Neurosci 15(3–5):313–319
Butterworth RF (2007) Neuronal cell death in hepatic encephalopathy. Metab Brain Dis 22(3/4):309–320
Butterworth RF, Giguère JF, Michaud J, Lavoie J, Pomier Layrargues G (1987) Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 6:1–12
Butterworth RF, Spahr L, Fontaine S, Pomier Layrargues G (1995) Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab Brain Dis 4:259–267
Cumings JN (1948) The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain 71(4):410–415
Cumings JN (1961) Soluble cerebral proteins in normal and oedematous brain. J Clin Pathol 14:289–294
Drayer B, Burger P, Darwin R, Riederer S, Herfkens R, Johnson GA (1986) MRI of brain iron. Am J Roentgenol 147(1):103–110
Eng SC, Taylor SL, Reyes V, Raaka S, Berger J, Kowdley KV (2005) Hepatic iron overload in alcoholic end-stage liver disease is associated with iron deposition in other organs in the absence of HFE-1 hemochromatosis. Liver Int 25(3):513–517
Erikson KM, Aschner M (2006) Increased manganese uptake by primary astrocyte cultures with altered iron status is mediated primarily by divalent metal transporter. Neurotoxicology 27(1):125–130
Felipo V, Butterworth RF (2002) Mitochondrial dysfunction in acute hyperammonemia. Neurochem Int 40(6):487–491
Giguère JF, Hamel E, Butterworth RF (1992) Increased densities of binding sites for the “peripheral-type” benzodiazepine receptor ligand 3H-PK 11195 in rat brain following portacaval anastomosis. Brain Res 585:295–298
Hazell AS, Norenberg MD (1997) Manganese decreases glutamate uptake in cultured astrocytes. Neurochem Res 22(12):1443–1447
Hazell AS, Desjardins P, Butterworth RF (1999) Chronic exposure of primary astrocyte cultures to manganese results in increased binding sites for “peripheral-type” benzodiazepine receptor ligand 3H-PK 11195. Neurosci Lett 271:5–8
Hazell AS, Normandin L, Norenberg MD, Kennedy G, Yi JH (2006) Alzheimer type II astrocytic changes following sub-acute exposure to manganese and its prevention by antioxidant treatment. Neurosci Lett 396(3):167–171
Hitoshi S, Iwata M, Yoshikawa K (1991) Mid-brain pathology of Wilson’s disease: MRI analysis of three cases. J Neurol Neurosurg Psychiatry 54:624–626
Kril JJ, Butterworth RF (1997) Diencephalic and cerebellar pathology in alcoholic and nonalcoholic patients with end-stage liver disease. Hepatology 26:837–841
Kuwert T, Hefter H, Scholz D et al (1992) Regional cerebral glucose consumption measured by positron emission tomography in patients with Wilson’s disease. Neurology 41:272
Lavoie J, Pomier Layrargues G, Butterworth RF (1990) Increased densities of “peripheral-type” benzodiazepine receptors in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Hepatology 11:874–878
Mzhe’lskaia TI, Larskiĭ EG, Pashchenko LA, Gladkikh SP, Ivanova-Smolenskaia IA, Markova ED (1989) Analysis of trace elements of the brain and liver tissues in Wilson’s disease. Zh Nevropatol Psikhiatr Im S S Korsakova 89(7):69–73
Norenberg MD (1987) The role of astrocytes in hepatic encephalopathy. Neurochem Pathol 6(1–2):13–33
Peterson C, Giguère JF, Cotman CW, Butterworth RF (1990) Selective loss of NMDA-sensitive 3H-glutamate binding sites in rat brain following portacaval anastomosis. J Neurochem 55:386–390
Pomier-Layrargues G, Spahr L, Butterworth RF (1995) Increased manganese concentrations in pallidum of cirrhotic patients. Lancet 345(8951):735
Reddy PV, Rao KV, Norenberg MD (2008) The mitochondrial permeability transition, and oxidative and nitrosative stress in the mechanism of copper toxicity in cultured neurons and astrocytes. Lab Invest 8(8):816–830
Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S (1987) Study of movement disorders and brain iron by MR. Am J Roentgenol 149(2):365–379
Schaefer M, Roelofsen H, Wolters H, Hofmann WJ, Müller M, Kuipers F, Stremmel W, Vonk RJ (1999) Localization of the Wilson’s disease protein in human liver. Gastroenterology 117(6):1380–1385
Scheline CT, Choi EH, Kin-Han JS, Dugan’ LL, Choi DW (2002) Cofactors of mitochondrial enzymes attenuate copper-induced death in vitro and in vivo. Ann Neurol 52:195–204
Schwarz J, Antonini A, Kraft E et al (1994) Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-singal intensity in de novo Wilson’s disease. Nature 44:1079
Soffer D, Sherman Y, Tur-Kaspa R, Eid A (1995) Acquired hepatocerebral degeneration in a liver transplant recipient. Acta Neuropathol 90:107–111
Spahr L, Butterworth RF, Fontaine S, Bui L, Therrien G, Millette P, Lebrun L-H, Zayed J, Leblanc A, Pomier Layrargues G (1996) Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 24:1116–1120
Watt NT, Hooper NM (2000) The response of neurones and glial cells to elevated copper. Brain Res Bull 55:219–224
Yin Z, Aschner JL, dos Santos AP, Aschner M (2008) Mitochondrial-dependent manganese neurotoxicity in rat primary astrocyte cultures. Brain Res 1203:1–11
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Butterworth, R.F. Metal Toxicity, Liver Disease and Neurodegeneration. Neurotox Res 18, 100–105 (2010). https://doi.org/10.1007/s12640-010-9185-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-010-9185-z